Conclusions Heart failure is costly and over a recent 10-year period, and direct expenditure related to HF increased markedly, mainly driven by inpatient costs. (Am Heart J 2017;186:63-72.)
Heart failure (HF) is associated with a substantial burden of morbidity and mortality in the United States. 1 In 2012, an estimated 5.7 million Americans 20 years or older had HF, and this number is projected to increase by 46% by the year 2030. 1 Over time, the hospitalizations for HF have remained high and are a significant concern for the US health care system, especially in terms of costs, which are heighted by the development and implementation of life-prolonging therapies, as well as aging of the population, which will lead to more people at risk for developing HF. 1 The HF costs are presumably driven by hospitalizations, home nursing or hospice service, and medical devices such as cardiac resynchronization therapy and ventricular assist devices, as well as transplantation. In the United States, total cost for HF was estimated to be $30.7 billion in 2012, with 68% being attributable to direct medical costs. 2 It is purported that the costs of HF have been rising or will rise over time in the United States. 2 However, extant studies on HF costs have been limited to short period, 3, 4 focused on a single aspect of expenses (mainly in-hospital costs), [5] [6] [7] [8] or have not had a national reach. 7, 8 These have either focused on limited period (a few years 3 or the last few months of life 4 ) and/or have mainly predated the widespread use of novel devices such as cardiac resynchronization and defibrillator 9 or left ventricular assist devices. 10 Changes in the use of and spending on hospitalizations, outpatient visits, and other medical services related to HF care remain unclear. Few studies have comprehensively quantified the change in the use of all these medical components in the United States or used nationally representative data. 7, 8 Overall, there is a lack of nationwide data over a prolonged period to reliability assess the trends in resource use among HF patients in the United States.
Using the framework of the Medical Expenditure Panel Survey Household Component (MEPS-HC), 11 the largest nationally representative survey of medical costs in the United States, we examined the changes over time in direct health care expenditures among US adults with HF from 2002 to 2011, with the aim of assessing how the changing demographics or quality of HF care the United States has impacted the cost of HF care for different US populations.
Methods

Data source and study population
We used data from the 2002-2011 MEPS. We identified 1,764 (weighted sample of 1,675,414) US adults (aged ≥18 years) with HF using an International Classification of Diseases, Ninth Revision (ICD-9) code from the MEPS-HC. The MEPS includes several waves of national surveys of families and individuals, their medical providers, and employers in the United States. It samples data on an average of 39,000 individuals per year to estimate the use of medical resources in the US population. The MEPS sample is drawn from reporting units in the previous year's National Health Interview Survey, a nationally representative sample (with oversampling for blacks and Hispanics) of the US civilian, noninstitutionalized population. The MEPS has a complex design consisting of clustering, stratification, and multistage and disproportionate sampling with oversampling of minorities. We included MEPS rounds of interviews covering 2 full calendar years from 2002 to 2011. The included participants were individuals 18 years and older with HF enrolled in the MEPS-HC during the 2002 to 2011 period. We merged data from HC survey of the medical condition files and full-year consolidated files using the unique person identifier (DUPERSID) on a one-to-one match. 12 We pooled 10-year data to ensure sufficient sample size and increase precision of our estimates. The medical conditions and procedures reported by the MEPS-HC related to HF were recorded by an interviewer as verbatim text and then converted by professional coders to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. The error rate for any coder did not exceed 2.5% on verification. To protect the confidentiality of respondents, fully specified ICD-9-CM codes were collapsed to 3 digits. 12 The MEPS collects information on health care use, expenditures, sources of payment, health status, the status of health insurance coverage, and demographic and socioeconomic characteristics of the civilian, noninstitutionalized population of the United States. Medical use and expenditures were collected from both household respondents and their medical providers.
Heart failure definition
People with HF were defined on the basis of self-report that led to medical visits or treatment within the interview year. The self-reported HF condition was transcribed and classified with ICD-9 codes using the ICD-9-CM diagnostic code 428 for HF. 12, 13 In the MEPS-HC, diagnoses codes are derived by professional coders based on survey interviews, and only the first 3 digits of these codes are reported in MEPS. Information on each respondent is annualized, in which a calendar year is the duration of time for which information is reported in MEPS. Respondents were included in the study based on the availability of an HF diagnosis at any time during the year, with no requirement for hospital admission to be included in the study.
Outcomes
Our focus was on direct medical costs because these constitute most HF-related costs. These costs include the total direct health care expenditures for the calendar year for each individual. The direct medical costs of HF were estimated by point of service, with the following point-of-service categories used: hospital (inpatient, outpatient, and emergency department [ED]), physician (officebased visits), prescription, home health, and other (including nursing home, rehabilitation, vision, medical supplies, dental). The costs include out-of-pocket payments and payments by private insurance, Medicaid, Medicare, and other sources; medical expenditures include (including office-based medical provider, hospital outpatient, ED, inpatient hospital [including zero night stays], pharmacy, dental, home health care, and other medical expenditures reported during the calendar year). The cost over the 2002-2011 period were be adjusted to the 2014 dollar value using the consumer price index obtained from the Bureau of Labor Statistics. 14 We used the 10-year pooled cross-sectional data and adjusted the analytic sampling weight variable by dividing it by the number of years being pooled. The sum of these adjusted weights represents the average annual population size for the pooled period. We combined 10 years of data (2002-2011) because for each year, these have a common variance structure necessary to ensure compatibility of our variables within the complex sample design.
Covariates
The covariates defined on the basis of self-report included demographic and clinical variables. Recent studies showed that sociodemographic and binary indicators of disease are important covariates that affect medical expenditures 15 and that binary indicators of disease are more effective in accounting for disease burden. [16] [17] [18] Covariates are age, sex, race/ethnicity, marital status, educational level, health insurance, metropolitan statistical area (MSA), region, poverty/income ratio (income level), calendar year, and comorbidities-diabetes, hypertension, cardiovascular diseases (CVDs), emphysema, joint pain, arthritis, and asthma. Binary indicators of comorbidities were based on self-report of a positive response to the question, "Have you ever been diagnosed with diabetes, hypertension, stroke, emphysema, joint pain, arthritis, or asthma?" Cardiovascular disease was defined by a positive response to a question, "Have you ever been diagnosed with coronary heart disease, angina, myocardial infarction, or other heart diseases?"
Age was categorized into 18-44, 45-64, and 65-85 years. Sex was dichotomized as male vs female, race/ethnicity as non-Hispanic white, non-Hispanic black, and Hispanic and others; marital status as married, widow/divorced/ single (nonmarried), and never married; education as less than high school (grade ≤12 years), high school, and college or more (grade ≥13 years); insurance as private, public only, and uninsured at all time in the year; and region as Northeast, Midwest, South, and West. Income level was defined as a percentage of poverty level and grouped in to 4 categories: poor (b125% federal poverty level), low income (≥125% and b200% federal poverty level), middle income (≥200% and b400% federal poverty level), and high income (≥ 400% poverty level). The MSA was coded as yes vs no at end of the year− (December 31) and categorized as MSA (urban) vs non-MSA (rural). 
Statistical analyses
The baseline characteristics of patients are presented by HF status, as percentages for categorical variables, with differences tested for using χ 2 tests. We estimated the unadjusted mean direct medical expenditures for individuals by HF status and then compared HF vs non-HF using test postestimation command with survey data. We then used a 2-part model to estimate the adjusted direct medical expenditures by HF status after controlling for confounding factors. The "margins" function in STATA is used to extrapolate the incremental effects and their standard errors from the combined first and second parts of the final model. The 2-part model was done using a 2-part generalized linear model allowing for mixed discrete-continuous variables. 19, 20 A probit model was used to estimate the probability of observing a zero vs positive medical expenditure, and a generalized linear model then estimated conditional on having a positive medical expenditure. [20] [21] [22] The use of GLM in the second part of the model has an advantage over log ordinary least squares because it relaxes the normality and homoscedasticity assumptions and avoids bias associated with retransforming to the raw scale.
14 The model addresses the zero concentration as well as the positive skewness of expenditures 23 and allows users to calculate incremental effects and standard errors from the 2 parts of the model. 20 We adjusted for sociodemographic factors (age, sex, race, marital status, education, health insurance, MSA, region, and income level) and comorbidities (diabetes, hypertension, CVD, stroke, emphysema, joint pain, arthritis, and asthma). To determine the family distribution for the generalized linear model, we used the modified Park test, 19, 20 taking into account the complex survey design. The Park test verifies the use of a gamma distribution with a log link as the best-fitting GLM for consistent estimation of coefficients and marginal effects of medical expenditures. 20, 24 The variance inflation factor for all predictors used in the 2-part model was estimated to rule out multicollinearity problems. We hypothesized that HF costs have been increasing over time, and these vary by age, presence of CVD (excluding HF), and race. The change in cost over time represents the mean cost per person per year over a 10-year period. We used standard pairwise comparison methods of Sidak, Scheffe, and Bonferroni to compare the pooled total mean health care expenditure among HF if the changes over 10 years were statistically significant. We compared total mean expenditures between 10-year groups For all the analyses, we accounted for the complex sampling design of MEPS data set by using sampling weight, variance estimation stratum, and primary sampling unit (clustering). A P value b.05 was considered statistically significant. All analyses were performed using STATA 14 (Stata Corp., College Station, TX). 25 
Results
Population characteristics
The characteristics of US adults with and without HF in the United States during the 2002-2011 period are shown in Table I . Of the weighted population representing 188,708,194 US adults aged 18 years or older, 0.9% had HF (with a prevalence of 0.1%, 0.76%, and 3.0%, among the age groups 18-44, 44-64, and ≥65 years, respectively). Heart failure was more frequent among older patients (≥65 years), non-Hispanic whites or non-Hispanic black (but less frequent among Hispanic or others), nonmarried, less than high school and high school graduates, publicly insured, rural and southern dwellers, and poor and low-income earners. People with HF had a higher frequency of hypertension, diabetes, CVD, stroke, and emphysema. The Table II) . Table II 
Adjusted comparison of individuals with and without HF
Accounting for demographics, comorbidities, and the effect of time, individuals with HF had $3,446 (95% CI 2,592-4,299) significantly higher expenditures than those without HF (Table III) . Individuals older than 45 years or 65 to 85 years old had significantly higher expenditures relative to those aged 18 to 44 years. Being female, high school or more, urban resident, and publicly insured were significantly associated with higher total health care expenditures compared with their reference groups. Non-Hispanic black or Hispanic/other race, nonmarried or never married, uninsured, residence in the South, and low, middle, or high income were significantly associated with lower total health care expenditures as compared with their counterparts. Comorbidities were associated with significantly higher expenditures, namely, diabetes $2,823 (95% CI 2,506-3,139), hypertension $1,334 (95% (Table III) . 
Economic burden of HF in the United States
We extrapolated the individual costs estimates, to the entire US population. Based on the unadjusted mean, the annual aggregate cost during the 2002-2011 period among adults with HF was estimated at $40 billion for the entire US population. At the population level, the adjusted total incremental cost for HF was $5.8 billion per year, when comparing those with HF with those without HF. The increase in HF costs was influenced by age (N65 years), a higher level of education, public insurance status, urban dwellers, and the presence of comorbidities. Our estimates of the population-level cost of HF are somewhat consistent with the global estimates. In 2012, the global economic cost of HF was estimated at $108 billion per annum, with direct costs accounted for~60% ($65 billion) and indirect costs accounted for~40% ($43 billion) of the overall spend. 26 The prevalence of HF increased over the study period. This may reflect more patients surviving with heart disease going on to developing HF and increased survival in those diagnosed as having HF during the study period. Better HF management over time, with implementation of quality of care standards (including the more widespread use of potentially costly devices [implantable cardiac defibrillators, cardiac resynchronization, and mechanical assist devices] and transplant) has improved survival and consequently costs. The upward trends in HF costs may also be partly explained by the improvement in detection of HF with preserved ejection fraction (HFpEF), as evidenced by studies indicating a temporal increase in the proportion of HFpEF cases detected in the community 27 as well as in hospitalizations for HFpEF. 28 There were a number of demographic and clinical characteristics associated with health care expenditures in patients with HF. Older age is associated with high costs, which is consistent with the increase in HF incidence with aging. Heart failure is the most common diagnosis in hospitalized elderly patients older than 65 years. 1 That the incremental costs in the US South are less than that in the rest of the country contrasts with the higher burden of HF in this region. It is well known that the southeastern region of the United States, for example (spanning from Georgia in the east to Oklahoma in the west-commonly referred to as the "stroke belt" owing to elevated rates of cerebrovascular events in this region), has an excess frequency of HF and its risk factors such as hypertension and diabetes mellitus, compared with the rest of the country, but with 69% higher age-adjusted mortality from HF than the national average. 29 Compared with the rest of the country, the south is may be more rural and has less teaching hospitals and thus less of an ability to address the burden of HF. Indeed, previous studies have shown that highest cost discharges for HF were more likely to be observed in urban and teaching hospitals. 30 Comorbidities that are also risk factors for HF such as obesity, sleep apnea, and diabetes mellitus also played a role in the rising burden of costs.
Our study provides important insights into factors associated with HF expenditures and thus has important implications for providing value-driven care to HF patients. The observed trends can be used to evaluate the effectiveness of the control and prevention programs or policies to stem the tide of HF, and point to the potential needs for a shift in the HF care delivery to a preventive approach, given the importance of preclinical HF. The study period predates that most of the Patient Protection and Affordable Care Act-based reforms and expenditures trends evident in this study establish a baseline in which subsequent expenditure trends can be compared. The disproportionately elevated costs of HF points to the need for efforts aimed at preventing the progression from asymptomatic stages of HF to more symptomatic, especially as projections of future HF costs (based on the MEPS data) indicate a doubling of costs from 2012 to 2030, if the HF incidence trends remain the same.
31
Comparisons with other studies Our study is the first of its kind to comprehensively examine US national trends in HF expenditures over a substantially long period (a decade). To our knowledge, no study has used national-level data to examine the trend of the financial burden of HF from the patients' or payers' perspectives including a quantification of all components of direct HF expenditures. We assembled data on inpatient, outpatient, and ED visits, and prescription medication use. This differs from previous studies on HF costs that have either focused on shorter periods (a few years 3, 32 or the last few months of life 4 ), on inpatient care/hospital costs only, [5] [6] [7] [8] 30 or have mainly predated the widespread use of novel devices such as cardiac resynchronization and defibrillator 9 or left ventricular assist device, 10 as well as heart transplant, which have costs that can potentially outweigh all the other HF costs. Of note, some aspects of the other studies that used the MSEP data differed significantly from ours. Our findings of increasing HF costs are in agreement with other reports that have examined the medical cost of HFs over time. Indeed, in the prospective Cardiovascular Health study (CHS,) the mean 10-year medical costs were significantly higher for the prevalent HF cohort ($54,704 vs $41,780) compared with those without HF. 33 Also, a study of the lifetime costs of HF showed that comorbidities such as diabetes mellitus significantly influence the expenditures. 
Strengths and limitations
The strengths of our study include the examination of trends in costs over a decade using a nationally representative sample, including multiple cost categories (inpatient, outpatient, prescription medications, dental, ED, and home health expenditures), and the use of a robust cost estimation method to assess incremental costs accounting for a variety of comorbidities and thus evaluating the independent effect of HF.
Our study had some limitations. First, comorbidities were based on self-report, thus having a potential for bias. However, self-reported comorbidities have been shown to be reliable. 35 Second, our estimates may be lower than the actual HF costs, as people with early stages of HF such as stage B, which is generally asymptomatic and accounts for an important fraction of those with HF (up to 50% of those with left ventricular systolic dysfunction are asymptomatic in the early phase of the condition), 36 may not have been accounted for. Third, institutionalized individuals who tend to be sicker but with a lower survival, and potential higher expenditures were not included in MEPS. Fourth, the HF costs were derived using survey data, which are subject to sampling error; thus, there is a certain degree of uncertainty in our point estimates that is difficult to quantify. Fifth, we did not include costs from the use of over-the-counter medications or investigate the indirect costs of lost productivity from morbidity premature mortality; the latter costs can be very substantial as indicated by a simulation that projected an increase in these from US$9.8 billion in 2012 to $16.6 billion by 2030. 31 The data on costs related to transitions of care in HF (hospice, short-term, and long-term care facilities) were not included in the estimates because these are not available in the MSEP surveys. We did not have data on the etiology of HF; we could not tell whether this was consecutive to ischemic heart disease or not. Our analysis did not also examine types of HF (HF with reduced ejection fraction [HFrEF] vs HFpEF) because the relative contribution of each type to costs has changed over time, given the continuous refinement in the capacity to diagnose HFpEF over recent years. Although some studies have suggested that preserved ejection fraction (≥50%) is associated with a 23.6% higher lifetime costs, 34 others have postulated that that the costs may be similar between those with HFrEF and HFpEF, 37 but the latter data were published at a time when detection of HFpEF was much less than currently and many of the new devices or late-stage therapies indicated for HFrEF were not in use. Finally, we also did not specifically have information on the contribution of costs related to the use of implantable cardiac defibrillators, cardiac resynchronization, left ventricular assist devices, and heart transplant. We also could not make a distinction between initial and repeat hospitalization, as well as whether the HF diagnosis was primary from secondary, given that these may have an impact on costs.
Conclusion
This study provides insights into high burden of HF-related costs in the United States over time, as well as the key determinants of high expenditures. Further research is needed to better characterize how the HF costs vary with health resource utilization overtime. Heart failure greatly contributes to the increase in health costs in the US population, indicating the potential savings from interventions to improve prevention and management of HF in the US population. Specifically, policy interventions directed toward reducing inpatient hospitalization use could have a significant impact on the trajectory of the overall HF-related costs. Improved cardiology and primary care access, systems of care, awareness on diet and physical activity, shift in care modalities (outpatient care/home health care), and reducing risk factor of HF by treating comorbidities are ways to minimize the substantial burden. The disproportionally high costs of HF point to the need for a shift of HF care toward a preventive approach and comprehensive disease management.
